J147 was discovered based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. It is an exceptionally potent, orally active and broadly neuroprotective compound has the ability to enhance memory in normal animals as well as to prevent memory deficits in Alzheimer's disease (AD) transgenic mice. The neurotrophic and memory-enhancing activities of J147 are associated with an increase in brain derived neurotrophic factor (BDNF) levels and the expression of BDNF responsive proteins, the enhancement of LTP, the preservation of synaptic protein, the reduction of amyloid plaques, etc. These pleiotrophic effects of a single molecule suggest that J147 has potential for the treatment of AD.

J147 is a very effective and oral neurotrophic molecule with an EC 50 of about 25nM [1]. In rat hippocampal neurons, J147 can resist the toxicity of amyloid, and its EC50 is about 200nM. J147 can promote the memory of normal rodents. In the genetically modified Alzheimer's mouse model, J147 can prevent the loss of synaptic protein and cognitive decline. The increase in the level of brain-derived neurotrophic factor (BDNF) and the expression of BDNF-related proteins, the enhancement of LTP, the preservation of synaptic proteins, the reduction of markers of oxidative stress and inflammation, the reduction of amyloid plaques, and the more Low levels of soluble Aβ1-42 and Aβ1-40 are all related to the neurotrophic effects of J147 and memory enhancement activities. In the aged mouse model of Alzheimer's disease, the function of J147 to promote memory is also related to the neurotrophic factor NGF it induces. These pleiotropic effects of a single molecule indicate that J147 has the potential to treat Alzheimer's disease (AD).